A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis

Science Translational Medicine

Volumn 3, Issue 101, 2011, Pages

  Owczarczyk, Kasia ^a,b   Lal, Preeti ^a   Abbas, Alexander R ^a   Wolslegel, Kristen ^a   Holweg, Cecile T J ^a   Dummer, Wolfgang ^a   Kelman, Ariella ^a   Brunetta, Paul ^a   Lewin Koh, Nicholas ^a   Sorani, Marco ^a   Leong, Diane ^a   Fielder, Paul ^a   Yocum, David ^a   Ho, Carole ^a   Ortmann, Ward ^a   Townsend, Michael J ^a   Behrens, Timothy W ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL MATURATION ANTIGEN; BIOLOGICAL MARKER; CD19 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; FCRL5 PROTEIN; IMMUNOGLOBULIN J CHAIN; MESSENGER RNA; OCRELIZUMAB; PLACEBO; POU2AZF1 PROTEIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; FCRL5 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMABLAST; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; BLOOD; CELL LINEAGE; COHORT ANALYSIS; DEMOGRAPHY; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PLASMA CELL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CELL LINEAGE; COHORT STUDIES; DEMOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULIN J-CHAINS; MALE; MIDDLE AGED; PLASMA CELLS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 80053124729     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002432     Document Type: Article

References (30)

1. D. E. Furst, E. C. Keystone, B. Kirkham, A. Kavanaugh, R. Fleischmann, P. Mease, F. C. Breedveld, J. S. Smolen, J. R. Kalden, G. R. Burmester, J. Braun, P. Emery, K. Winthrop, B. Bresnihan, F. De Benedetti, T. Dörner, A. Gibofsky, M. H. Schiff, J. Sieper, N. Singer, P. L. Van Riel, M. E. Weinblatt, M. H. Weisman, Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann. Rheum. Dis. 67 (Suppl. 3), iii2-iii25 (2008).
2. M. E. Reff, K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, N. Hanna, D. R. Anderson, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445 (1994).
3. M. C. Genovese, J. L. Kaine, M. B. Lowenstein, J. Del Giudice, A. Baldassare, J. Schechtman, E. Fudman, M. Kohen, S. Gujrathi, R. G. Trapp, N. J. Sweiss, G. Spaniolo, W. Dummer; ACTION Study Group, Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 58, 2652-2661 (2008).
4. P. Emery, R. Fleischmann, A. Filipowicz-Sosnowska, J. Schechtman, L. Szczepanski, A. Kavanaugh, A. J. Racewicz, R. F. Van Vollenhoven, N. F. Li, S. Agarwal, E. W. Hessey, T. M. Shaw; DANCER Study Group, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54, 1390-1400 (2006).
5. S. B. Cohen, P. Emery, M. W. Greenwald, M. Dougados, R. A. Furie, M. C. Genovese, E. C. Keystone, J. E. Loveless, G. R. Burmester, M. W. Cravets, E. W. Hessey, T. Shaw, M. C. Totoritis; REFLEX Trial Group, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793-2806 (2006).
6. P. Emery, A. Deodhar, W. F. Rigby, J. D. Isaacs, B. Combe, A. J. Racewicz, K. Latinis, C. Abud-Mendoza, L. J. Szczepanski, R. A. Roschmann, A. Chen, G. K. Armstrong, W. Douglass, H. Tyrrell, Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy inMTX iNadequate rEsponders (SERENE)). Ann. Rheum. Dis. 69, 1629-1635 (2010).
7. J. Sellam, H. Hendel-Chavez, S. Rouanet, K. Abbed, B. Combe, X. Le Loët, J. Tebib, J. Sibilia, Y. Taoufik, M. Dougados, X. Mariette, B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study. Arthritis Rheum. 63, 933-938 (2011).
8. T. Dörner, N. Kinnman, P. P. Tak, Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol. Ther. 125, 464-475 (2010).
9. S. Dass, A. C. Rawstron, E. M. Vital, K. Henshaw, D. McGonagle, P. Emery, Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58, 2993-2999 (2008).
10. Y. K. Teng, E. W. Levarht, M. Hashemi, I. M. Bajema, R. E. Toes, T. W. Huizinga, J. M. Van Laar, Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum. 56, 3909-3918 (2007).
11. M. J. Leandro, G. Cambridge, M. R. Ehrenstein, J. C. Edwards, Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54, 613-620 (2006).
12. P. Roll, T. Dörner, H. P. Tony, Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 58, 1566-1575 (2008).
13. A. Palanichamy, P. Roll, R. Theiss, T. Dörner, H. P. Tony, Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab. Arthritis Rheum. 58, 3665-3674 (2008).
14. E. M. Vital, S. Dass, A. C. Rawstron, M. H. Buch, V. Goëb, K. Henshaw, F. Ponchel, P. Emery, Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re-treatment. Arthritis Rheum. 62, 1273-1279 (2010).
15. M. Odendahl, H. Mei, B. F. Hoyer, A. M. Jacobi, A. Hansen, G. Muehlinghaus, C. Berek, F. Hiepe, R. Manz, A. Radbruch, T. Dörner, Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105, 1614-1621 (2005).
16. M. C. Jaimes, O. L. Rojas, E. J. Kunkel, N. H. Lazarus, D. Soler, E. C. Butcher, D. Bass, J. Angel, M. A. Franco, H. B. Greenberg, Maturation and trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children. J. Virol. 78, 10967-10976 (2004).
17. S. Moir, A. S. Fauci, B cells in HIV infection and disease. Nat. Rev. Immunol. 9, 235-245 (2009).
18. J. H. Anolik, J. Barnard, A. Cappione, A. E. Pugh-Bernard, R. E. Felgar, R. J. Looney, I. Sanz, Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50, 3580-3590 (2004).
19. A. E. Hauser, G. F. Debes, S. Arce, G. Cassese, A. Hamann, A. Radbruch, R. A. Manz, Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J. Immunol. 169, 1277-1282 (2002).
20. C. Clavel, L. Nogueira, L. Laurent, C. Iobagiu, C. Vincent, M. Sebbag, G. Serre, Induction of macrophage secretion of tumor necrosis factor α through Fcγ receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 58, 678-688 (2008).
21. M. Yang, H. Hase, D. Legarda-Addison, L. Varughese, B. Seed, A. T. Ting, B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J. Immunol. 175, 2814-2824 (2005).
22. G. Cambridge, W. Stohl, M. J. Leandro, T. S. Migone, D. M. Hilbert, J. C. Edwards, Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54, 723-732 (2006).
23. T. Vallerskog, M. Heimbürger, I. Gunnarsson, W. Zhou, M. Wahren-Herlenius, C. Trollmo, V. Malmström, Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 8, R167 (2006).
24. S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, A. Langer-Gould, C. H. Smith; HERMES Trial Group, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008).
25. J. H. Stone, P. A. Merkel, R. Spiera, P. Seo, C. A. Langford, G. S. Hoffman, C. G. Kallenberg, E. W. St Clair, A. Turkiewicz, N. K. Tchao, L. Webber, L. Ding, L. P. Sejismundo, K. Mieras, D. Weitzenkamp, D. Ikle, V. Seyfert-Margolis, M. Mueller, P. Brunetta, N. B. Allen, F. C. Fervenza, D. Geetha, K. A. Keogh, E. Y. Kissin, P. A. Monach, T. Peikert, C. Stegeman, S. R. Ytterberg, U. Specks; RAVE-ITN Research Group, Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221-232 (2010).
26. A. G. Polson, B. Zheng, K. Elkins, W. Chang, C. Du, P. Dowd, L. Yen, C. Tan, J. A. Hongo, H. Koeppen, A. Ebens, Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int. Immunol. 18, 1363-1373 (2006).
27. P. Ciotti, A. Garuti, A. Ballestrero, G. Cirmena, M. Chiaramondia, P. Baccini, E. Bellone, P. Mandich, Reliability and reproducibility of a RNA preamplification method for low-density array analysis from formalin-fixed paraffin-embedded breast cancer samples. Diagn. Mol. Pathol. 18, 112-118 (2009).
28. A. R. Abbas, D. Baldwin, Y. Ma, W. Ouyang, A. Gurney, F. Martin, S. Fong, M. Van Lookeren Campagne, P. Godowski, P. M. Williams, A. C. Chan, H. F. Clark, Immune response in silico (IRIS): Immune-specific genes identified from a compendium of microarray expression data. Genes Immun. 6, 319-331 (2005).
29. R. D. Page, TreeView: An application to display phylogenetic trees on personal computers. Comput. Appl. Biosci. 12, 357-358 (1996).
30. Acknowledgments: We thank the physicians and patients who participated in these studies. We also thank W. Y. Lin and F. Martin for provision of the B cell lineage microarray data. Funding: The clinical studies were funded by Genentech, a member of the Roche Group, and Biogen Idec Inc. The biomarker studies were funded by Genentech Inc. Author contributions: W.D., A.K., P.B., P.F., and D.Y. designed and carried out the clinical studies. K.O., K.W., C.T.J.H., P.L., M.S., D.L., W.O., M.J.T., and T.W.B. designed and carried out the biomarker studies. K.O., A.R.A., N.L.-K., P.L., C.H., W.O., M.J.T., and T.W.B. analyzed the data. K.O., P.L., W.O., M.J.T., and T.W.B. wrote the paper. Competing interests: The authors are full-time employees of Genentech, a member of the Roche Group. Genentech has filed patent application(s) related to this work on biomarkers that predict nonresponse to anti-CD20 therapy.